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Stem cell transplantation has been investigated to rescue experimental liver failure and is promising to offer an alternative therapy
to liver transplantation for liver diseases treatment. Several clinical studies in this field have been carried out, but the therapeutic
benefit of this treatment is still controversial. A major obstacle to developing stem cell therapies in clinic is being able to visualize
the cells in vivo. Imaging modalities allow optimization of delivery, detecting cell survival and functionality by in vivo monitoring
these transplanted graft cells. Moreover, theranostic imaging is a brand new field that utilizes nanometer-scale materials to glean
diagnostic insight for simultaneous treatment, which is very promising to improve stem cell-based therapy for treatment of liver
diseases. The aim of this review was to summarize the various imaging tools that have been explored with advanced molecular
imaging probes. We also outline some recent progress of preclinical and clinical studies of liver stem cells transplantation. Finally,
we discuss theranostic imaging for stem cells transplantation for liver dysfunction and future opportunities afforded by theranostic
imaging.
1. Introduction
Acute liver failure and cirrhosis result from a variety of acute
or chronic hepatic injuries [1, 2]. Up till now, liver transplan-
tation has been considered as the primary treatment for acute
liver failure and cirrhosis and various end-stage liver diseases.
However, this procedure is hindered by the lack of donor
organs, technical difficulties, complications associated with
immune rejection, the requirement for lifelong immunosup-
pression, and financial considerations [3–5]. Therefore, to
develop novel treatments that can either be effective curative
and/or affect the underlying pathophysiology of the liver
disease is urgently needed.
Stem cell transplantation has been suggested as an effec-
tive alternate approach for liver dysfunction [6–8]. For maxi-
mal efficacy, these therapies require transplanted cell delivery
to targeted tissues followed by successful cell engraftment. So
far, numbers of clinic trials of stem cells transplantation for
liver dysfunction have been carried out. By September 2016,
more than 200 clinical trials had been registered when Clini-
calTrials.govwas searched for the terms “stem cells AND liver
diseases”. Among these clinical studies, some have indicated
to be well tolerated and safe and confer beneficial effects in
patients with liver failure, by enhancing liver function and
reducing ascites and overall mortality without any major
side effects [9–13]. However, the benefits of this emerging
therapy for liver dysfunction in recent finished clinical trials
are still conflicting. Some studies demonstrated there was no
significant therapeutic effect to liver dysfunction [14]. Other
concerns and critical issues remain unanswered regarding the
long-term safety [9, 10, 12, 15–22]. Therefore, several meta-
analyses have concluded that controversies remain in this
rapidly developing field [23–26].
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Meanwhile, several critical issues in clinical protocols
require further investigation, such as the optimal type of
cell types, the optimal therapeutic timing, the most effective
stem cells amount, the best route of administration, and the
primary endpoints. One thing is clear that there is an unmet
clinical need to monitor the transplanted stem cells in vivo.
Hence, in vivo visualization of transplanted stem cells with
a robust, quantitative imaging method is essential for the
monitoring of cell implantation, homing, and differentiation.
The purpose of this current review is to summarize the latest
developments of the various imaging modalities dedicated to
monitor stem transplantation for liver dysfunctions; preclinic
and clinic studies are emphasized; in addition, theranostic
imaging and their future applications are also highlighted.
2. Imaging Methods to Monitor Transplanted
Stem Cells in Animal Models
Noninvasive tracking of stem cells could facilitate its clinical
translation. So far all major imaging modalities have been
introduced to monitor transplanted stem cells for liver
diseases. Numbers of animal studies have demonstrated that
imaging modalities are essential for developing efficacious
cell therapies for liver damage animal models.
2.1. Optical Imaging. Optical imaging,mainly based on retro-
viral vectors or enzymes to express fluorescent proteins,
includes fluorescence imaging and bioluminescence imaging
(BLI). Both these imaging methods have been tested for in
vivo monitoring transplanted stem cells in liver.
Yukawa et al. investigated whether quantum dots (QDs)
labeling using octa-arginine peptide (R8) for adipose tissue-
derived stem cells (ASCs) could be applied for in vivo
fluorescence imaging in mice with acute liver failure. The
results demonstrated that heparin was effective in increasing
the accumulation of transplanted ASCs in the liver using
this imaging technology [27]. In another study, Akhan et al.
conjugated a novel polymer basedwater-dispersible nanopar-
ticles (CPN) with improved photostability, high fluorescent
quantum yield, and noncytotoxicity compared to conven-
tional dyes and quantum dots. The results showed that the
labeled mesenchymal stem cells (MSCs) migrated to the
liver and retained their labels in an in vivo liver regenera-
tion model. These studies demonstrated that the utilization
of florescence labeling could be a promising tool for the
tracking of stem cells transplanted in liver to understand
differentiation and homing mechanisms [28]. Wang et al.
investigated upconversion nanoparticles- (UCNPs-) labeled
mouseMSCs intravenous transplanted into mice and imaged
using an in vivo upconversion luminescence (UCL) imaging
system, observing the translocation ofMSCs from lungwhere
they initially accumulated, to liver [29]. Li et al. compared
three-delivery routes for the MSCs transplantation to liver,
including inferior vena cava (IVC), the superior mesenteric
vein (SMV), and intrahepatic (IH) injection using in vivo
BLI. Results showed that MSCs were firstly trapped inside
the lungs, and no detectable homing to the liver and other
organs was observed after IVC infusion; after SMV infusion,
MSCs were dispersedly distributed and stayed as long as 7-
day posttransplantation in the liver. By IH injection, MSCs
distribution was only localized in the injection region of the
liver [30]. In another study reported by the same group, Liu
et al. evaluated survival of transplanted human MSCs in the
mice liver after intrahepatic transplantation and the role of
intrahepatic natural killer (NK) cells by in vivo BLI. A gradual
decline in bioluminescent signals from transplanted MSCs
in liver was observed. Interestingly, compared to the control
group, the survival time and retention of intrahepatic MSCs
decreased more rapidly in the NK-activated group, which
indicated that activated NK cells potentially accelerated the
rejection of transplanted MSCs [31].
2.2. Nuclear Imaging. Wu et al. investigated the biodistribu-
tion of human placental deciduas basalis derived mesenchy-
mal stem cells (PDB-MSCs) in nude mice after intravenous
injection by carbon radioisotope labeling thymidine ((14) C-
TdR), which was able to incorporate into new DNA strands
during cell replication. Labeled PDB-MSCs grafts were found
mainly in the lung, liver, spleen, stomach, and left femur of
the recipient animals at the whole observation period. This
work demonstrated that (14) C-TdR labeling did not alter the
biological characteristics of human placental MSCs and that
this labeling method had potential to be used to quantify the
transplanted cells in preclinical studies [32].
2.3.Magnetic Resonance Imaging (MRI). Magnetic resonance
imaging provides high-resolution (ranging from 50 𝜇m in
animals up to 300𝜇minwhole body clinical scanners) images
capable of tracking stem cells in vivo without invasiveness
and without the use of ionizing radiation. Stem cells need to
be prelabeled with contrast probes for cell tracking studies
by MRI. The probes for MRI noninvasively identification
and tracking of transplanted cells include negative contrast
agents, as superparamagnetic iron-oxide (SPIO) and ultra-
small superparamagnetic iron-oxide (USPIO) particles, and
positive contrast agents, such as gadolinium. They both
have been tested in small animal models for stem cells
transplantation studies.
An emerging approach to visualizing stem cells by MR is
to label the stem cells with perfluorocarbon (PFC) nanoemul-
sions, which can be detected with 19Fluorine MRI.
2.3.1. SPIO. Bos et al. evaluated in vivo tracking of intravas-
cularly injected SPIO labeledMSCs using a conventional 1.5 T
MR imaging system. After labeled MSC injection, damaged
liver had diffuse granular appearance. Cells were detected for
up to 12 days in liver. They concluded that MRI could in vivo
monitor intravascularly administered SPIO labeled MSCs in
liver [33]. Arbab et al. developed a method of delivering
SPIO labeled MSCs to a targeted area in an animal model
by applying an external magnet. SPIO labeled MSCs were
injected intravenously to animals, and an external magnet
was placed over the liver area of the animals. MRI signal
intensity (SI) changes in the liver were monitored at different
time points using MRI. Interestingly, SI decrease in the liver
after injection of MSCs was greater in rats with external
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magnets and returned gradually to that of control rat livers
at approximately day 29. The results proved that the external
magnets retained the labeled MSCs in the region of interest
[34]. Cai et al. evaluated in vivo MRI for tracking the SPIO
labeled MSCs transplanted into rat liver through hepatic
arterial infusion. The labeled stem cells in liver could be
detected and monitored in vivo with a 1.5 T clinical MR
scanner for up to 7 days after transplantation [35]. Ju et
al. tracked intrasplenically transplanted MSCs labeled with
SPIO by using MRI in vivo in a liver damaged rat model.
These studies demonstrated that MSCs could be effectively
labeled with approximately 100% efficiency. Migration of
transplanted labeled cells to the liver was successfully doc-
umented with in vivo MRI [36, 37]. Choi et al. labeled
human MSCs with SPIO and green fluorescence protein
(GFP). LabeledMSCs were transplanted into the portal veins
of immunosuppressed, hepatic-damaged rat models. Serial
MR imaging showed signal loss in the liver of transplanted
cells in the early period of transplantation [38]. Zhong et
al. assessed SPIO labeled MSCs that were transplanted via
the portal vein to rats with hepatic fibrosis using MRI. T2∗-
weighted MR imaging indicated lower signal in liver [39].
Kim et al. used a fluorescent magnetic nanoparticle (MNP),
which had both magnetic and optical features, containing a
ferritin core and a silica shell, and the inner portion of silica
shell filled fluorescent materials for stem cell tracking studies.
Intrasplenically transplantedMSCs labeledwithMNP in liver
cirrhosis rat model were monitored with 3T MR scanner.
The results showed that the liver-to-muscle contrast-to-noise
ratios at 3 and 5 h after cell transplantation was significantly
lower than that of preinjection group [40].
2.3.2. Gadolinium Based Probes. Shuai et al. transfected
human umbilical cord derived MSCs with gadolinium-
diethylenetriaminepentaacetic acid (Gd-DTPA) for in vitro
MRI. The result showed that minimum 5 × 104 Gd-DTPA-
labeled stem cells could be detected with MRI in vitro. The
trace duration time was about 12 days without compromising
either cell viability or cell differentiability [41]. The same
group also determined double labeling of MSCs with Gd-
DTPA and fluorescent dye PKH26. Gd-DTPA and PKH26
were used to label the stem cells. MRI and fluorescence
microscopy were used to detect the double-labeled MSCs.
Their in vitro studies demonstrated that the proliferation and
differentiation abilities of MSCs were not affected by double
labeling using Gd-DTPA and PKH26 [42]. Furthermore, Pan
et al. assessed trackingGd-DTPA and PKH26-labeled human
umbilical cord MSCs using MRI in vivo. The T1 values and
signal intensity on T1-weighted imaging of labeled cells were
significantly higher than the control. The signal intensity on
T1-weighted imaging of labeled cells was retained over 14
days in vivo [43]. The results demonstrated that this labeling
method was reliable and efficient; the in vivo studies of
transplanted cells in liver using this labeling method need to
be further investigated.
2.3.3. Perfluorocarbon Based MRI. Another technique under
evaluation for imaging injected stem cells in vitro and in
vivo is based on perfluorocarbon (PFC) formulations, whose
advantage is the high specificity due to the virtual absence
of fluor from the body. The fluorine signal can be accurately
quantified from the MR images [44].
An emerging approach to imaging stem cells by MRI is
to label the stem cells with perfluorocarbon nanoemulsions,
which can be detected with 19F MRI [45–47]. The 19F
nucleus is particularly suitable for labeling as its relative MR
sensitivity is only 17% less than that of 1H. Since the level of
background 19F signal in host tissue is virtually absent [45],
overlaying the 19F image on a conventional anatomical image
allows for unambiguous, quantitative tracking of labeled cells
in vivo.
A number of promising findings have been reported for
the use of 19F labeling, including (1) intracellular labeling; (2)
the lack of cellular toxicity; (3) the stability of cell labeling
up to 21 days postlabeling; (4) positive signal with no back-
ground observedwith 19FMRI; (5) biodistribution visualized
by overlaying a 19F image of labeled cells on a 1H anatomical
image; (6) determination of the local concentration of labeled
cells by quantitative 19F MRI [48].
2.4. Emerging Imaging Modality: Magnetic Particle Imaging
(MPI). MPI is noninvasive and offers near-ideal image con-
trast, depth penetration, high sensitivity, and superb quan-
titativeness for single-cell tracking. Unlike MRI that applies
magnetic resonance principles, MPI directly detects the
iron-oxide nanoparticle-tagged cells using magnetic fields.
These properties make MPI both ultrasensitive and linearly
quantitative and very promising for monitoring transplanted
cells in vivo. Conolly group from UC Berkeley firstly utilized
MPI to monitor transplanted stem cells in vivo in animal
model. Their first MPI cell tracking study demonstrated 200-
cell detection limit in vitro and in vivo monitoring of graft
clearance over 87 days in a rat model [49]. In a more recent
study, this group imaged the intravenously transplanted
MSCs using MPI. The results showed that labeled MSCs
immediately entrapped in lung tissue posttransplantation and
then relocated to the liver within one day. Longitudinal MPI-
CT imaging demonstrated a clearance half-life of MSC iron-
oxide labels in the liver at 4.6 days [50].These first in vivoMPI
results indicate that MPI offers strong utility for quantitating
the transplanted stem cells labeled using SPIO.
3. Preclinic Imaging of Large Animal Models
and Clinical Applications
Although stem cell transplantation based therapies have been
clinically applied to patients, the fate of graft cells remains
unknown. Small animal studies have demonstrated the fea-
sibility and important role of in vivo imaging technologies
for in vivo monitoring of transplanted stem cells. The next
step is to conduct preclinic studies using large animals that
are necessary for translation of these cutting edge imaging
technologies to clinic.
3.1. Preclinic Imaging of Transplanted Stem Cells in Liver with
Large Animal Models. Ito-Fujishiro et al. evaluated track
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implanted peripheral blood mononuclear cells labeled with
SPIO on days 0 and 7 after intravenous injection into a
cynomolgus monkey using a 3T MRI scanner. Labeled cells
were visualized in the liver on MR images T2-weighted
sequences [51]. Shi et al. investigated tracking of SPIO labeled
MSCs after intraportal transplantation to swine models of
acute liver injury. Results showed that signal intensity loss
in the livers of swine models by SPIO labeling on the
T2∗WI sequence persisted until 2 weeks after transplanta-
tion [52]. Spriet et al. compared the cell distribution and
quantification shortly after intraportal vein, systemic intra-
venous and splenic injections of technetium-99m- (99mTc-
) hexamethyl-propylene amine oxime (HMPAO) labeled
MSCs in healthy beagle dogs. Scintigraphic images were
obtained using gamma camera after cell transplantation to
target the liver, which showed that, after the portal injection,
diffuse homogeneous high uptake was observed through the
liver; the systemic intravenous injection resulted in cells
trapped in the lungs, whereas splenic injection led to MSCs
mild splenic retention and homogeneous diffuse hepatic
uptake [53].
3.2. The First Clinical Applications of Molecular Imaging on
Stem Cells Transplantation for Liver Diseases. Gholam-
rezanezhad et al. investigated the biodistribution of autol-
ogous 111In-oxine labeled MSCs, after peripheral infusion
in four cirrhotic patients was investigated using SPECT
imaging. After intravenous infusion, the radioactivity was
first observed to accumulate in the lungs of recipients. Then
the radioactivity gradually increased in the liver and spleen
in these four patients. Radiolabeled MSCs relocalized in liver
and spleen: radioactivity decreased from 33.5% to 2% in lung
and increased from 2% to 42% in spleen. This first clinic
imaging study demonstrated that cell labeling with 111In-
oxine was a suitable tool for tracking peripheral vein infused
MSC distribution [54]. In a more recent case report study,
Defresne et al. assessed biodistribution of 111-Indium DTPA
labeled adult derived human liver stem cells (ADLHSC)
from healthy donor using SPECT imaging after infusion
through the portal vein in a patient with glycogenosis type 1A.
Following infusion through the portal vein, SPECT imaging
observed ADHLSC spread strictly within the targeted organ
of liver until 5 days [55].
4. Theranostic Imaging of Stem Cells
The term “theranostics” refers to a rapidly developing ap-
proach that combines diagnostic imaging and molecular
therapy [56]. By packaging the two modalities of diagnostic
imaging and molecular therapy together, the application
of theranostic imaging is promising to overcome undesir-
able selective biodistribution differences between diagnostic
imaging probes and therapeutic agents [57–60]. To achieve
higher sensitivity and increasemolecular specificity, the novel
two-in-one theranostic agents for various imaging tools have
been developed. Not only can the novel imaging probes be
functional as imaging tools, but they can also be useful as a
carrier for controlled releasing of therapeutic moieties [61].
4.1. Improving Liver Function by Delivering Therapeutic Plas-
midDNA. Pang et al. utilized a complex of SPIOnanoparticle
coated with polyethylene glycol-grafted polyethylenimine
(PEG-g-PEI-SPION) as an MRI probe that can track of rat
boneMSCs and also act as a carrier for the plasmidDNA.The
complex labeled MSCs were modified by a plasmid encoding
human hepatocyte growth factor (HGF) attached in the MRI
visible vector complex and transplanted into fibrotic rat livers.
The results proved that these transplanted grafts effectively
restored albumin production and significantly suppressed
transaminase activities in the liver damaged animal models.
Meanwhile, the transplanted MSCs displayed a sensitive
signal on T2/T2∗-weighted MR images, which enabled in
vivo tracking of the cells for up to 14 days after transplantation
[62].
4.2. Promoting Transplanted Cell Survival by Combined
Cytokines Delivery. Kempen et al. designed a theranostic
mesoporous silica nanoparticle that could offer ultrasound
and MRI signal to guide transplanted cells and also served
as a drug release reservoir of insulin-like growth factor
(IGF) that could promote MSCs survival. The results showed
that the presence of IGF increased cell survival up to 40%
versus unlabeled cells in vitro [63]. Pulavendran et al. com-
pared cirrhotic mice received either hematopoietic stem cells
(HSC) or MSC with or without HGF incorporated chitosan
nanoparticles (HGF-CNP). Serum levels of selected liver
protein and enzymes were significantly increased in the com-
bination of MSC and HGF-CNP (MSC+HGF-CNP) treated
group. These findings indicated that HGF-CNP enhanced
the differentiation of stem cells into hepatocytes. The results
demonstrated MSCs transplantation in combination with
HGF-CNP could be a promising treatment for liver cirrhosis
[64].
4.3. In Vivo RNA Interference: siRNAs and microRNAs Deliv-
ery Carriers. RNA interference is a naturally occurring
endogenous regulatory process where short double-stranded
RNA including small interference RNA (siRNA) andmicroR-
NAs could induce sequence-specific posttranscriptional gene
silencing. In vivo RNA interference therapy represents a
promising therapeutic strategy, but the barriers for delivery
siRNAs or microRNAs hamper this therapeutic method
to reach their intended targets cells or tissues and to
exert their gene silencing activity [65]. Theranostic probes
labeled on the transplanted stem cells actually could serve
as siRNA or microRNA carriers. Zhao et al. synthesized
poly-sodium4-styrenesulfonate (PSS) and poly-allylamine
hydrochloride (PAH) coated AuNR-based nanoparticles,
which could deliver siRNA against LSD1 to induce the
hepatocyte lineage differentiation of human MSCs in vitro
[66]. These methods need to be further tested in vivo
before it could eventually translate to clinical applications.
MicroRNAs are endogenous small noncoding RNAs that
regulate key processes of cells. Studies have been reported on
the posttranscriptional regulation of hepatic differentiation
and regenerative capacities in MSCs by microRNAs [67, 68].
Gomes et al. reported the use of biodegradable nanoparticles
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containing perfluoro-1,5-crown ether (PFCE), a fluorine-
based compound (NP170-PFCE) that could track cells in
vivo by MRI and efficiently release miRNA. NP170-PFCE
conjugatedwithmiRNA132 could accumulatewithin the cell’s
endolysosomal compartment increased 3-fold the survival of
endothelial cells (ECs) transplanted in vivo [69]. This novel
theranostic technology potentially could be transferred to
stem cells transplantation for liver diseases in future.
4.4. Stem Cells Can Be Used as a Unique Carrier for Ther-
apeutic Agents. Zhao et al. loaded adipose-derived MSCs
with SPIO-coated gold nanoparticles (SPIO@AuNPs), which
is a MR contrast probe that can be activated to generate
heat when irradiated with near-infrared laser, and tested
their effects against liver injury and hepatocellular carcinoma
(HCC) in mice. The results showed that in vivo MR imaging
confirmed the active homing of AD-MSCs to liver. Upon
laser irradiation, the SPIO@AuNP-loaded AD-MSCs could
thermally ablate surrounding HCC tumor cells.
This study demonstrated that AD-MSC could act as an
efficient carrier for therapeutic agents to liver injuries or
HCC. The results showed that SPIO@AuNP–loaded AD-
MSCs proved a promising theranostic agent for liver injury
and HCC [70].
4.5. Preventing Teratoma Formation in Target Organs. One
reason for controversial application of stem cell treatment is
the possibility associated with tumor formation in the recipi-
ent. For promoting therapeutic effect, stem cellsmay undergo
substantial manipulation such as differentiation and in vitro
expansion, and this can lead to possible genetic aberrations
and carcinogenesis [71]. To address the intractable issues such
as the teratoma formation encountered in human embryonic
stem cell (hESC) for therapeutic in clinic, Chung et al.
hypothesized that serial manganese-enhanced MRI would
have theranostic effect to assess hESC survival, teratoma
formation, and hESC-derived teratoma reduction through
intracellular accumulation ofMn2+.The study demonstrated
that systemic administration ofMnCl2 enabled simultaneous
monitoring and elimination of hESC-derived teratoma cells
by higher intracellular accumulation of Mn2+ [72].
5. Conclusions and Future Perspectives
Stem cell therapy as a part of regenerative medicine provides
promising alternatives for the treatment of liver injuries and
diseases. The increasing application of stem cells transplan-
tation for liver diseases treatments created the demand for
long-term and quantitative in vivo cell trackingmethods [71].
In this review, promising in vivo imaging methods for stem
cell monitoring after transplantation in liver are shown. It
is unlikely that one technique will answer all questions, but
use of a multimodal approach will be the most appropriate
approach to addressing the number of issues posed in this
exciting field. The selection of a set or a combination of
appropriate imaging approaches will depend on the goal of
the experiment, on the experimental subject under study, and
also on the availability of multimodality imaging facilities
and probes. In addition, new imaging modalities including
Cherenkov illumination imaging (CLI), photoacoustic imag-
ing (PAI), and surface enhanced Raman imaging (SERI) are
developing rapidly. The application of these new strategies
will also play a helpful role in the advancement of the field of
stem cell therapy [73]. Mostly, although still in its infant stage
of development, theranostic imaging definitely represents a
promising new direction for in vivo stem cell transplantation.
The maturation of multifunctional theranostic imaging may
indeed revolutionize stem cell transplantation approach for
liver diseases and beyond [74].
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